Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Oct 16, 2025
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Award
Common Stock
2025-10-15+39,682→ 67,392 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.